{"analyses":[{"ciLowerLimit":"-1.387","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.63","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.79","estimateComment":"The treatment can be considered beneficial if the mean difference (treatment - control) slope is negative","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.24","paramType":"Slope","paramValue":"2.121","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.0697","value":"27.3836"},{"groupId":"OG001","spread":"3.424","value":"31.4324"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.3339","value":"31.8406"},{"groupId":"OG001","spread":"3.4737","value":"34.1857"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.4625","value":"26.8203"},{"groupId":"OG001","spread":"4.095","value":"33.2941"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.7939","value":"35.807"},{"groupId":"OG001","spread":"4.0405","value":"32.2807"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.0875","value":"34.625"},{"groupId":"OG001","spread":"3.6481","value":"33.3774"}]}],"title":"24m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"B-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average N-terminal Pro B-type Natriuretic Peptide","type":"SECONDARY","unitOfMeasure":"pg/mL"}